This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Sequenom

BOSTON ( TheStreet) -- You might not think it, but Sequenom (SQNM - Get Report) and have something in common.

Ten years ago, on March 10, 2000, the dot-com bubble burst. The tech-heavy Nasdaq peaked at 5,132 and then proceeded to slide downhill fast, taking with it the fortunes of investors who naively thought that anything with the letter "e" in front its name was a golden ticket.

The online pet supply "e-tailer" came to mind as I was putting together this week's Biotech Stock Mailbag and reading through a dozen or so emails of reader comments about my coverage of Sequenom.
Mailbag was a very hot stock back in the early days of the aughts. (Remember its mascot, the talking sock puppet?) Never mind that it really didn't make much sense for pet owners to buy large bags of kitty litter and puppy chow online and wait days for delivery. Forget that relied on discounted shipping to attract customers, and the company actually lost money on every order. Back in 2000, e-tailers were a hot ticket on Wall Street and investors were more than happy to overlook the obvious and fatal flaws in's business plan.

Today, investors seem to have imbued Sequenom with some of that reckless disregard for reality. The troubled developer of non-invasive fetal gene tests, which blew up last year when data for a Down's Syndrome test had to be thrown out, is nonetheless enjoying a stock resurgence, with shares essentially doubling since last December. The stock closed Thursday at $8.01.

But as BNET's Jim Edwards summed it up nicely this week, Sequenom investors are "projecting their wildly optimistic expectations onto a real blank slate of a company."

I wonder how much angry email he got for that remark? I know my inbox filled up fast after my last Sequenom column in which I dissected Sequenom's fuzzy math being used by one analyst to justify her newly minted $16 price target.

"Gofigure" writes, "So, what are you saying here is? Sequenom will not have any viable test out this year? What is your proof of it? Are you shorting the stock?"

"Stockfundmanager" takes Jim Cramer and me to task for being "wrong about Sequenom since $2.55 up until the current $8.60 and you keep bashing instead of admitting you are wrong. You are becoming suspect of having a motive to your bashing... My price target is $25 versus Cramer's of $3. We will see who is right me or Cramer."
1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
APPA $13.07 0.46%
DNDN $0.06 -6.02%
ITMN $73.89 -0.03%
ARNA $1.52 0.00%
CVM $0.48 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs